35 related articles for article (PubMed ID: 34286335)
1. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1229-1236. PubMed ID: 32152703
[TBL] [Abstract][Full Text] [Related]
4. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
[TBL] [Abstract][Full Text] [Related]
5. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study.
Huang J; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Li X; Liu G; Hu H; Huang S; Yang X
BMC Cancer; 2023 Aug; 23(1):812. PubMed ID: 37649021
[TBL] [Abstract][Full Text] [Related]
6. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine.
Fuksiewicz M; Kowalska M; Kolasinska-Cwikla A; Kotowicz B
Endocr Connect; 2022 Sep; 11(9):. PubMed ID: 35900770
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.
Puchades-Carrasco L; Jantus-Lewintre E; Pérez-Rambla C; García-García F; Lucas R; Calabuig S; Blasco A; Dopazo J; Camps C; Pineda-Lucena A
Oncotarget; 2016 Mar; 7(11):12904-16. PubMed ID: 26883203
[TBL] [Abstract][Full Text] [Related]
9. Left Lung High-Density Shadow Combined with Elevated NSE Ultimately Confirmed as Pulmonary Aspergillosis.
Jiang J; Li Q; Ren HQ; Zhao Q; Yang W; Fu AS; Ge YL
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948488
[TBL] [Abstract][Full Text] [Related]
10. Advances and Challenges in Nanomaterial-Based Electrochemical Immunosensors for Small Cell Lung Cancer Biomarker Neuron-Specific Enolase.
Mehta D; Gupta D; Kafle A; Kaur S; Nagaiah TC
ACS Omega; 2024 Jan; 9(1):33-51. PubMed ID: 38222505
[TBL] [Abstract][Full Text] [Related]
11. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y; Tao L; Qiu J; Xu J; Yang X; Zhang Y; Tian X; Guan X; Cen X; Zhao Y
Signal Transduct Target Ther; 2024 May; 9(1):132. PubMed ID: 38763973
[TBL] [Abstract][Full Text] [Related]
12. Beyond
Ni J; Huang Y; Li C; Yin Q; Ying J
Mol Ther Oncolytics; 2023 Dec; 31():100750. PubMed ID: 38075246
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Specific Tumoral Markers, Inflammatory Status, and Vitamin D Metabolism before and after the First Chemotherapy Cycle in Patients with Lung Cancer.
Crintea A; Drugan C; Constantin AM; Lupan I; Fekete Z; Silaghi CN; Crăciun AM
Biology (Basel); 2022 Jul; 11(7):. PubMed ID: 36101414
[TBL] [Abstract][Full Text] [Related]
14. Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.
Dong H; Liang X; Gao Y; Cai Y; Li X; Miao J; Wang W; Hu B; Li H
Thorac Cancer; 2022 May; 13(9):1258-1266. PubMed ID: 35315227
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
Mimori T; Shukuya T; Ko R; Okuma Y; Koizumi T; Imai H; Takiguchi Y; Miyauchi E; Kagamu H; Sugiyama T; Azuma K; Namba Y; Yamasaki M; Tanaka H; Takashima Y; Soda S; Ishimoto O; Koyama N; Kobayashi K; Takahashi K
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053494
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.
Yan P; Han Y; Tong A; Liu J; Wang X; Liu C
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34286335
[TBL] [Abstract][Full Text] [Related]
17. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
18. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
19. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
